92138-16-4Relevant academic research and scientific papers
Anticancer anilinoacridines. A process synthesis of the disubstituted amsacrine analog CI-921
Brennan,Colbry,Leeds,Leja,Priebe,Reily,Showalter,Uhlendorf,Atwell,Denny
, p. 1469 - 1476 (2007/10/02)
An improved process for the synthesis of bulk quantities of the clinical amsacrine analog CI-921 is reported. Described also are detailed analytical and spectroscopic data for this agent.
Potential Antitumor Agents. 48. 3'-Dimethylamino Derivatives of Amsacrine: Redox Chemistry and in Vivo Tumor Activity
Atwell, Graham J.,Rewcastle, Gordon W.,Baguley, Bruce C.,Denny, William A.
, p. 652 - 658 (2007/10/02)
Structure-activity relationships for a series of acridine-substituted 3'-N(CH3)2 derivatives of the clinical antileukemic drug amsacrine (1) are reported.The parent (unsubstituted) compound 3 has activity against the Lewis lung solid tumor that is superior to amsacrine(1), the new clinical amsacrine analogue 4, and the recently developed 3'-NHCH3 derivative 2.Although the compounds generally bind less well to DNA and are less dose potent in vivo than either their amsacrine (3'-OCH3) or 3'-NHCH3 analogues, they show very high levels of antitumor activity, with the 4-OCH3 derivative capable of effecting 100percent cures of the Lewis lung solid tumor.The broad structure-activity relationships for acridine substitution more closely resemble those of the amsacrine than the 3'-NHCH3 series, with 4-substituted and 4,5-disubstituted compounds showing the highest activity.
